Pan-TRK IHC shows some utility as a diagnostic and surrogate marker for NTRK screening however, physiologic or non-specific expression may lead to false-positive results.

10 months ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase) • TPM4 (Tropomyosin 4)

NTRK3 fusion • ETV6-NTRK3 fusion • NTRK3 positive • TPM4-NTRK3 fusion • NTRK fusion

VENTANA pan-TRK (EPR17341) Assay

over3years

[VIRTUAL] Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification. (ASCO 2021)

Several rare and novel fusions were identified; a sarcoma with TPM4-NTRK3 fusion responded to larotrectinib, while a sarcoma with PML-JAK1 fusion did not respond to ruxolitinib, and a sarcoma with IL7R-BCL2 fusion progressed on venetoclax . NGS profiling led to a targeted therapy with a clinical benefit rate of 12% in this cohort . NGS profiling led to a change in diagnosis in 5% of this cohort . Multi-institutional collaborations to track outcomes of matched therapy would help determine the utility of therapies in rare cancers and unusual alterations.

over 3 years ago

Clinical • Next-generation sequencing • Tumor Mutational Burden • IO biomarker

TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TPM4 (Tropomyosin 4)

TMB-H • NTRK3 fusion • MET amplification • IL7R-BCL2 fusion • PML-JAK1 fusion • TPM4-NTRK3 fusion • BCL2 fusion

Venclexta (venetoclax) • Xalkori (crizotinib) • Vitrakvi (larotrectinib) • Jakafi (ruxolitinib)